| HOME >> MEDICINE >> TECHNOLOGY |
18,05415,030Operating loss from continuing operations
(4,658)(2,806)Other Income and Expense: Interest and other income
3379Interest expense
(1,094)(2,059)Gain on debt extinguishment upon conversion of convertible notes
--598Gain on debt extinguishment upon repurchase of convertible notes
11,284--Gain (loss) on net change in fair value of derivative assets and liabilities
(1,813)68Total other income (expense), net
8,410(1,314)Net income (loss) from continuing operations
3,752(4,120)Discontinued Operations:Net income (loss) from discontinued operations,
net of income taxes
61(15,376)Less: Loss attributed to noncontrolling interests in
consolidated entities – discontinued operations
--7,500Net income (loss) attributed to Verenium
$
3,813$
(11,996)Basic and diluted net income (loss) per share:
Continuing Operations
$
.30$
(0.34)Discontinued Operations
$
--$
(1.28)Net income (loss) attributed to Verenium
$
.30$
(0.99)Shares used in computing basic and diluted net income (loss) per share
12,60412,057Verenium CorporationCondensed Consolidated Balance Sheet Data(unaudited, in thousands)March 31,December 31,20112010Cash and cash equivalents
$
46,150$
87,929Accounts receivable, net
9,9686,708Inventory, net
5,7725,316Restricted cash, short term
5,000--Other current assets
3,0162,694Restricted cash, long term
--5,000Property and equipment, net
2,9683,134Other noncurrent assets
650976Total assets
$
73,524$
,757Current liabilities, excluding deferred revenue, restructuring and liabilities of discontinued operations
$
,076$
,849Deferred revenue, current
2,334894Accrued restructuring, current
1,735--Convertible notes, at carrying value (face value of $44.
'/>"/>
| SOURCE Verenium Corporation Copyright©2010 PR Newswire. All rights reserved |